A Case Report of FRα-Positive, Long-Duration, Multi-Line Recurrent Platinum-Resistant High-Grade Serous Ovarian Cancer Treated with Sacituzumab Govitecan

DOI: 10.12201/bmr.202610.00064

•  

  Abstract: Objective: To explore the clinical efficacy, safety, and acquired resistance characteristics of sacituzumab govitecan in FRα-positive, long-course, multi-line refractory platinum-resistant high-grade serous ovarian cancer. Methods: A retrospective analysis was conducted on a patient with high-grade serous ovarian cancer who had recurrent disease after multiple lines of anti-tumor therapy, was platinum-resistant, and exhibited FRα-positive expression. The patient received monotherapy with sacituzumab govitecan, followed by regular follow-up, dynamic monitoring of tumor markers CA125 and HE4, and imaging changes to evaluate efficacy and adverse reactions. Results: The patient initially showed significant benefits from sacituzumab govitecan treatment, with notable decreases in CA125 and HE4 levels, and imaging indicated stable tumor lesions, effectively controlling the disease. The drug-related adverse reactions were mild and tolerable. However, in the later stages of treatment, the patient developed acquired resistance, with persistent increases in CA125 and HE4 levels. Conclusion: Sacituzumab govitecan can provide short-term benefits for FRα-positive, multi-line refractory platinum-resistant high-grade serous ovarian cancer patients, with favorable safety. However, resistance progression is prone to occur in the later clinical stages, necessitating further clarification of resistance mechanisms and exploration of combination treatment strategies to delay resistance, offering clinical reference for the precise treatment of this refractory ovarian cancer.

  Key words: Advanced-stage serous ovarian cancer; Platinum-resistant recurrence; Folate receptor alpha; Sacituzumab; Antibody-drug conjugate

  Submit time: 28 October 2026

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• 胡芷晴, Pan Shan, Zhu Weili. Advances in Research on Ferroptosis Reversing Platinum Resistance in Ovarian Cancer. 2025. doi: 10.12201/bmr.202512.00070

  houjianfeng, liaohuadong, chenjieping. Current application and prognostic value of retroperitoneal lymphadenectomy in patients with low-grade serous ovarian cancer. 2026. doi: 10.12201/bmr.202610.00001

  Li Hui, Tong Keke. Clinical observation on the treatment of malignant ascites of ovarian cancer (spleen and kidney yang deficiency type) with compound soap and thorn soup combined with calatin abdominal thermal perfusion. 2026. doi: 10.12201/bmr.202604.00092

  Zhang Xinzhong. Research progress on folate receptor positive circulating tumor cells and the occurrence and development of non-small cell lung cancer. 2025. doi: 10.12201/bmr.202506.00024

  The current status of self-regulated fatigue in patients with recurrent ovarian cancer and its correlation with perceived burden and social supportTao Xinhui,Yu Juancai, Lin Lina. 2024. doi: 10.12201/bmr.202406.00033

  Zhang Aiqin. Zhang Aiqins Experience in Treating Ovarian Cancer after Operation and Chemotherapy. 2024. doi: 10.12201/bmr.202411.00016

  che xuan. Feasibility and Safety of Transvaginal Hysterectomy for Postmenopausal Patients with Non-prolapsed High-grade Cervical Lesions. 2025. doi: 10.12201/bmr.202501.00068

  Chen Shuling, Chen Yun, Shu Qijin. Exploring the Medication Patterns of Patent Compound Therapy for Ovarian Cancer Based on Data Mining. 2025. doi: 10.12201/bmr.202510.00008

  Zhao Qun. Young Chemotherapy Resistant Choriocarcinoma：Case Report and Literature Review. 2024. doi: 10.12201/bmr.202411.00007

  xiaogongliang, wuqiang, zhangqinghua, liutingting. Clinical Analysis and Literature Review of a Case of Colorectal Cancer with Ovarian, Hepatic, and Renal Metastases During Pregnancy. 2026. doi: 10.12201/bmr.202610.00002

• ID	Submit time	Number	Download
  1	2026-09-11	10.12201/bmr.202610.00064V1	Download

• Public  Anonymous  To author only Submit Comments